Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
| The first 150 words of the full text of this article appear below. |
EDITOR
Peveler et al confirm the inefficacy of antidepressant drugs in
the treatment of mild depression.1 I reviewed this subject
when working as a medical assessor with responsibility for new product
licences for the Committee on Safety of Medicines during 1979-81. The
standard antidepressants imipramine and amitriptyline had been studied
in randomised controlled trials in different types of depression. Both
drugs had been tested against placebo in patients with mild depression,
and both were found to be no better than placebo; in contrast, in
studies with mixed categories of patients with depression and in
hospital studies efficacy was clearly shown.
Despite this background, new antidepressants were granted licences
without restrictions on the basis of studies with no specific evidence
of efficacy in mild depression. Placebo studies with the newer
antidepressants to determine valid criteria for treatment of depression
in general practice are long overdue. As far as counselling against
non-compliance
Read all Rapid Responses